Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Diffuse aggressive lymphomas are a major group of non-Hodgkin's lymphomas with a rapidly progressive clinical course.
• Historically, these lymphomas were often fatal.
• Recent advancements have focused on improving patient survival and treatment efficacy.

Purpose of the Study:

• To review the current treatment strategies for diffuse aggressive lymphomas.
• To evaluate the effectiveness of chemotherapy, radiation therapy, and biologic response modifiers.
• To discuss the prognosis and future therapeutic avenues for patients.

Main Methods:

• Review of recent clinical studies and treatment protocols for diffuse aggressive lymphomas.
• Analysis of survival rates, response rates, and relapse rates associated with various therapies.
• Examination of the role of combination chemotherapy, radiation therapy, and biologic agents.

Main Results:

• Intermittent high-dose combination chemotherapy has significantly increased survival times.
• Advanced disease shows complete response rates of 85% and a 73% 3-to-5-year survival rate.
• Radiation therapy is crucial in early stages; salvage chemotherapy offers brief responses; biologic therapies show limited efficacy in aggressive lymphomas.

Conclusions:

• High-dose chemotherapy regimens have markedly improved outcomes for diffuse aggressive lymphomas.
• While effective, intensive regimens are not tolerated by all patients, necessitating further research.
• Biologic therapies, including interferons and monoclonal antibodies, show limited benefit for aggressive lymphomas but may help in indolent subtypes.